Loading...
Market
What will be the outcome of CAR-T therapy trials for lupus by end of 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Published results in peer-reviewed medical journals or official trial results
Story
CAR-T Therapy Shows Promise for Lupus Amid Serious Side Effects
Nov 30, 2024, 01:46 PM
Chimeric Antigen Receptor T-cell (CAR-T) therapy, initially approved for certain blood cancers, is showing promise in early tests for treating autoimmune diseases such as lupus. This innovative therapy is designed to eliminate entire classes of immune cells, potentially addressing conditions like lupus. However, the treatment poses risks of serious side effects. Researchers are also exploring other gene and immune therapies, including a universal gene therapy for Diamond-Blackfan anemia, which aims to correct the disorder regardless of the patient’s specific mutation. Additionally, a drug approved for heart failure has demonstrated potential in killing aggressive ovarian cancer cells and resensitizing relapsed tumors to chemotherapy in preclinical studies. These advancements highlight significant progress in the use of gene and immune-based treatments for various diseases.
View original story
Similar markets
Complete remission • 25%
Partial remission • 25%
No change • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
0-5 • 25%
6-10 • 25%
11-20 • 25%
21+ • 25%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Improved efficacy • 25%
Reduced side effects • 25%
Lower cost of treatment • 25%
Other • 25%
Increased survival rate • 25%
Reduced secondary cancer rate • 25%
Improved quality of life • 25%
Other • 25%